Experts will debate whether gliptins (Onglyza, etc) increase cardiovascular risk in patients with type 2 diabetes

November 2013

Experts will debate whether gliptins (Onglyza, etc) increase cardiovascular risk in patients with type 2 diabetes.

Gliptins are popular because they're taken orally once a day...and rarely cause hypoglycemia or weight gain.

But they cost about $3 a day...and reduce A1C less than 1%.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

Migraine New Canadian guidelines will improve treatment of acute migraines
Heart Failure bigger emphasis on preventing hospital admissions for heart failure
Diabetes Experts will debate whether gliptins (Onglyza, etc) increase cardiovascular risk in patients with type 2 diabetes
Supplements whether the probiotic Cardioviva (CAR-dee-oh-VEE-vuh) lowers cholesterol
Substance Use Disorder new approaches to managing alcohol dependence
Pregnancy more questions about which cough, cold, and allergy meds to use during pregnancy and breastfeeding
Women's Health paroxetine for hot flashes
Antithrombotics how to manage antiplatelet therapy in patients already taking anticoagulants
Pediatrics many parents exhibit signs of "fever phobia" and overuse antipyretics in their kids
ADHD Intuniv XR (in-TOO-niv), a new once-daily extended-release guanfacine for ADHD in kids
Epilepsy new option for partial onset seizures called Fycompa (fi-COM-puh, perampanel)